Search research articles
Contact Us
Filters
Showing results (1-10 of 75) with videos related to
Page
of 8
Sort By:
Leukemia & Lymphoma
|
May 24, 2011
Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Raoul Tibes, Ruben A Mesa
Journal of Hematology & Oncology
|
March 7, 2014
Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
Raoul Tibes, Ruben A Mesa
Frontiers in Oncology
|
January 11, 2020
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
Raoul Tibes, James M Bogenberger
Expert Opinion on Emerging Drugs
|
August 24, 2013
Emerging drugs for polycythemia vera
Raoul Tibes, Ruben A Mesa
Leukemia Research
|
March 31, 2012
Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques
Raoul Tibes, Ruben A Mesa
Annual Review of Pharmacology and Toxicology
|
April 12, 2005
Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics
Raoul Tibes, Jonathan Trent, Razelle Kurzrock
Targeted Oncology
|
April 23, 2020
Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond
Jun H Choi, James M Bogenberger, Raoul Tibes
Current Hematologic Malignancy Reports
|
December 16, 2011
Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Madappa N Kundranda, Raoul Tibes, Ruben A Mesa
Hematology (Amsterdam, Netherlands)
|
April 18, 2012
JAK2 inhibitors and their impact in myeloproliferative neoplasms
Holly L Geyer, Raoul Tibes, Ruben A Mesa
Expert Opinion on Investigational Drugs
|
September 21, 2012
JAK2 inhibitors in the treatment of myeloproliferative neoplasms
Raoul Tibes, James M Bogenberger, Holly L Geyer, et al.
Page
of 8
Search research articles
Search
Showing results (1-10 of 75) with videos related to
Sort By:
Page
of 8
Leukemia & Lymphoma
|
May 24, 2011
Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Raoul Tibes, Ruben A Mesa
Journal of Hematology & Oncology
|
March 7, 2014
Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
Raoul Tibes, Ruben A Mesa
Frontiers in Oncology
|
January 11, 2020
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
Raoul Tibes, James M Bogenberger
Expert Opinion on Emerging Drugs
|
August 24, 2013
Emerging drugs for polycythemia vera
Raoul Tibes, Ruben A Mesa
Leukemia Research
|
March 31, 2012
Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques
Raoul Tibes, Ruben A Mesa
Annual Review of Pharmacology and Toxicology
|
April 12, 2005
Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics
Raoul Tibes, Jonathan Trent, Razelle Kurzrock
Targeted Oncology
|
April 23, 2020
Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond
Jun H Choi, James M Bogenberger, Raoul Tibes
Current Hematologic Malignancy Reports
|
December 16, 2011
Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Madappa N Kundranda, Raoul Tibes, Ruben A Mesa
Hematology (Amsterdam, Netherlands)
|
April 18, 2012
JAK2 inhibitors and their impact in myeloproliferative neoplasms
Holly L Geyer, Raoul Tibes, Ruben A Mesa
Expert Opinion on Investigational Drugs
|
September 21, 2012
JAK2 inhibitors in the treatment of myeloproliferative neoplasms
Raoul Tibes, James M Bogenberger, Holly L Geyer, et al.
Page
of 8